When the cutoff level of the WT1-332-specific IL-10 IR index was set as 1.15, the group with a higher WT1-332-specific IL-10 released from PBMCs had a significantly lower completion rate and a higher rate of tumor progression than the group with lower WT1-332-specific IL-10 released from PBMCs (Table 4). The gene discussed is IL10; the disease is neoplasm.